Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score
- PMID: 32557780
- DOI: 10.1111/his.14181
Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score
Abstract
Aims: Tumour-infiltrating lymphocytes (TILs) are prognostic in invasive breast cancer; however, their prognostic significance in ductal carcinoma in situ (DCIS) has not been established. The Oncotype DX (ODX) Breast DCIS Score test is a genomic assay used to predict the local recurrence risk. The aims of this study were to quantify TILs in DCIS by the use of three methodologies, and correlate them with the ODX DCIS Score.
Methods and results: We studied 97 DCIS cases, all with an ODX DCIS Score. Cases with a low ODX DCIS Score were considered as one group, and those with an intermediate/high ODX Score were considered together. TILs were quantified on haematoxylin and eosin-stained slides. The methodologies used to quantify TILS included assessment of stromal TILs, assessment of touching TILs, and assessment of circumferential TILS. In cases with >5% stromal TILS, the percentage of stromal TILS was considered to be high. In cases with a mean number of more than five touching TILs per DCIS duct, TILs were considered to be present. The ODX DCIS Score was intermediate/high in 27 (28%) cases and low in 70 (72%) cases. There were >5% stromal TILs in 33 (34%) cases, and more than five touching TILs per DCIS duct in 15 (15%) cases; circumferential TILs were present in nine (9%) cases. In univariate analysis, a low ODX DCIS Score showed significant associations with absent touching TILS (P = 0.027), stromal TILs < 5% (P = 0.031), and absent circumferential TILs (P = 0.002). In logistic regression analysis adjusted for necrosis and nuclear grade, touching TILs and circumferential TILs showed significant associations with the ODX DCIS Score, whereas stromal TILs did not.
Conclusions: Our results suggest that both the presence of TILs and the spatial arrangement of TILs or close proximity of TILs to DCIS, and TILs touching or encircling DCIS, may be predictive of recurrence.
Keywords: Oncotype Dx DCIS Score; breast; ductal carcinoma in situ; tumour-infiltrating lymphocytes.
© 2020 John Wiley & Sons Ltd.
Similar articles
-
Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.Histopathology. 2022 Jan;80(2):291-303. doi: 10.1111/his.14539. Epub 2021 Sep 22. Histopathology. 2022. PMID: 34379814
-
Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.Mod Pathol. 2018 Aug;31(8):1226-1236. doi: 10.1038/s41379-018-0040-8. Epub 2018 Mar 20. Mod Pathol. 2018. PMID: 29559742
-
The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.Br J Cancer. 2020 May;122(10):1496-1506. doi: 10.1038/s41416-020-0797-7. Epub 2020 Mar 17. Br J Cancer. 2020. PMID: 32203210 Free PMC article.
-
Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast.Breast Cancer Res Treat. 2024 Nov;208(1):9-18. doi: 10.1007/s10549-024-07466-9. Epub 2024 Aug 24. Breast Cancer Res Treat. 2024. PMID: 39180593 Review.
-
Prognostic role of immune infiltrates in breast ductal carcinoma in situ.Breast Cancer Res Treat. 2019 Aug;177(1):17-27. doi: 10.1007/s10549-019-05272-2. Epub 2019 May 27. Breast Cancer Res Treat. 2019. PMID: 31134489 Review.
Cited by
-
Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model.Cancers (Basel). 2023 Mar 23;15(7):1922. doi: 10.3390/cancers15071922. Cancers (Basel). 2023. PMID: 37046583 Free PMC article.
-
Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights.Discov Oncol. 2025 Jul 28;16(1):1435. doi: 10.1007/s12672-025-03288-3. Discov Oncol. 2025. PMID: 40721545 Free PMC article. Review.
-
Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ.Oncoimmunology. 2021 Mar 18;10(1):1875637. doi: 10.1080/2162402X.2021.1875637. Oncoimmunology. 2021. PMID: 33796401 Free PMC article.
-
Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group.Br J Cancer. 2022 Jun;126(11):1589-1594. doi: 10.1038/s41416-022-01708-7. Epub 2022 Jan 18. Br J Cancer. 2022. PMID: 35043007 Free PMC article.
-
Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast.Cancers (Basel). 2022 Aug 13;14(16):3916. doi: 10.3390/cancers14163916. Cancers (Basel). 2022. PMID: 36010908 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J. Clin. 2017; 67; 7-30.
-
- Wapnir I, Digman J, Fisher B, et al. Long term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized trials for DCIS. J. Natl Cancer Inst. 2011; 103; 478-88.
-
- Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J. Natl Cancer Inst. Monogr. 2010; 41; 162-77.
-
- Giannakeas V, Sopik V, Narod S. Association of radiotherapy with survival in women treated for ductal carcinoma in situ with lumpectomy or mastectomy. JAMA Netw. Open 2018; 1; e181100.
-
- McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J. Clin. Oncol. 2015; 33; 709-15.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical